Related Experiment Video
Updated: Jun 17, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies
Jeetendra Kumar Nag1, Priyanga Appasamy1, Hodaya Malka1
1Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel.
Abstract:
Cancer cells depend on specific oncogenic pathways or present a genetic alteration that leads to a particular disturbance. Still, personalized and targeted biological therapy remains challenging, with current efforts generally yielding disappointing results. Carefully assessing onco-target molecular pathways can, however, potently assist with such efforts for the selection of patient populations that would best respond to a given drug treatment. RNF43, an E3 ubiquitin ligase that negatively regulates Wnt/frizzled (FZD) receptors by their ubiquitination, internalization, and degradation, controls a key pathway in cancer. Recently, additional target proteins of RNF43 were described, including p85 of the PI3K/AKT/mTOR signaling pathway and protease-activated receptor 2 (PAR2), a G-protein-coupled receptor that potently induces β-catenin stabilization, independent of Wnts. RNF43 mutations with impaired E3 ligase activity were found in several types of cancers (e.g., gastrointestinal system tumors and endometrial and ovarian cancer), pointing to a high dependency on FZD receptors and possibly PAR2 and the PI3K/AKT/mTOR signaling pathway. The development of drugs toward these targets is essential for improved treatment of cancer patients.
Insights
Understanding the RNF43 E3 ubiquitin ligase is crucial for targeted cancer therapy. Its role in regulating Wnt/Frizzled receptors and other pathways offers new therapeutic targets for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Targeted cancer therapies face challenges due to pathway complexity.
- RNF43 (E3 ubiquitin ligase) regulates Wnt/Frizzled (FZD) receptors, a key cancer pathway.
- RNF43 also targets PI3K/AKT/mTOR pathway components and protease-activated receptor 2 (PAR2).
Purpose of the Study:
- To highlight the significance of RNF43 in cancer.
- To identify RNF43 as a potential therapeutic target.
- To explore RNF43's interaction with FZD receptors, PAR2, and PI3K/AKT/mTOR signaling.
Main Methods:
- Literature review of RNF43's molecular functions.
- Analysis of RNF43 mutations in various cancer types.
- Examination of RNF43's role in Wnt/FZD, PAR2, and PI3K/AKT/mTOR pathways.
Main Results:
- RNF43 mutations impairing its ligase activity are found in gastrointestinal, endometrial, and ovarian cancers.
- RNF43's regulation of FZD receptors is critical.
- RNF43 influences beta-catenin stabilization via PAR2, independent of Wnts.
Conclusions:
- RNF43 is a vital regulator in multiple cancer-associated signaling pathways.
- Targeting RNF43 and its associated pathways (FZD, PAR2, PI3K/AKT/mTOR) is essential for developing effective cancer treatments.
- Further drug development targeting these pathways holds promise for personalized cancer therapy.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
01:23Negative Regulator Molecules
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...